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ABSTRACT
Background. Distal pancreatectomy with celiac axis
resection (DP-CAR) is a treatment option for selected
patients with pancreatic cancer involving the celiac axis. A
recent multicenter European study reported a 90-day
mortality rate of 16%, highlighting the importance of
patient selection. The authors constructed a risk score to
predict 90-day mortality and assessed oncologic outcomes.
Methods. This multicenter retrospective cohort study
investigated patients undergoing DP-CAR at 20 European
centers from 12 countries (model design 2000–2016) and
three very-high-volume international centers in the United
States and Japan (model validation 2004–2017). The area
under receiver operator curve (AUC) and calibration plots
were used for validation of the 90-day mortality risk
model. Secondary outcomes included resection margin
status, adjuvant therapy, and survival.
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Results. For 191 DP-CAR patients, the 90-day mortality
rate was 5.5% (95 confidence interval [CI], 2.2–11%) at 5
high-volume (C 1 DP-CAR/year) and 18% (95 CI, 9–30%)
at 18 low-volume DP-CAR centers (P = 0.015). A risk
score with age, sex, body mass index (BMI), American
Society of Anesthesiologists (ASA) score, multivisceral
resection, open versus minimally invasive surgery, and
low- versus high-volume center performed well in both the
design and validation cohorts (AUC, 0.79 vs 0.74;
P = 0.642). For 174 patients with pancreatic ductal ade-
nocarcinoma, the R0 resection rate was 60%, neoadjuvant
and adjuvant therapies were applied for respectively 69%
and 67% of the patients, and the median overall survival
period was 19 months (95 CI, 15–25 months).
Conclusions. When performed for selected patients at
high-volume centers, DP-CAR is associated with accept-
able 90-day mortality and overall survival. The authors
propose a 90-day mortality risk score to improve patient
selection and outcomes, with DP-CAR volume as the
dominant predictor.
Distal pancreatectomy with celiac axis resection (DP-
CAR) may lead to a radical resection for selected patients
with locally advanced pancreatic cancer involving the
celiac axis. The procedure relies on collateral flow from the
superior mesenteric artery via the pancreatic head arcade to
the liver and stomach. Some centers perform preoperative
embolization of the hepatic and/or left gastric artery1 to
maximize the formation of collaterals and reduce the risk
of ischemia-related complications, but evidence in support
of this practice is lacking.
A recent systematic review of 250 patients,2 four sub-
sequent single-center studies of 17–80 patients,3–6 and a
pan-European retrospective multicenter study of 68
patients7 all suggested that DP-CAR for pancreatic ductal
adenocarcinoma leads to an acceptable overall survival
ranging from 17 to 35 months. Despite this survival ben-
efit, the 90-day mortality rate after DP-CAR can be as high
as 16–18%.7–9 A clinical risk score that evaluates the risk
of mortality before surgery could inform shared decision
making and improve outcomes through better patient
selection. However, such a score is difficult to design for
low-volume procedures such as DP-CAR.
A recent study and subsequent international validation
(Klompmaker et al., unpublished data) proposed a risk
prediction model for major morbidity (including mortality)
after standard distal pancreatectomy based on age, sex,
American Society of Anesthesiology (ASA) score, body
mass index (BMI), multivisceral resection, and open versus
minimally invasive approach.10 This model reflects the
general risk for severe adverse events compared with the
risk for specific complications after distal pancreatectomy.
Although DP-CAR is a more extensive procedure, the
existing model could serve as a basis for a clinical risk
score. It is known that this method of adjustment is superior
to designing of a new model with many fewer patients.11
This study aimed to create a 90-day mortality risk score
for an existing cohort from 20 European DP-CAR centers
and to perform an international validation for a combined
cohort derived from three very-high-volume centers in the
United States and Japan. We hypothesized that the risk
score could successfully identify high-risk patients with
little expected benefit from DP-CAR.
METHODS
For this multicenter retrospective study, we used a
design cohort, previously collected at 20 European high-
volume pancreas surgery centers,7 and a retrospective
multicenter validation cohort, which included patients from
Johns Hopkins Hospital (JHH), Baltimore, MD, USA
(2004–2017), the University of Pittsburgh Medical Center
(UPMC), Pittsburgh, PA, USA (2007–2017), and the
Wakayama Medical University Hospital (WMUH),
Wakayama, Japan (2004–2017).
We added and updated the previously published ser-
ies3,4,12 comprising the validation cohort. We used the
design cohort to create a 90-day mortality risk score based
on the coefficients of a previously validated prediction
model for major morbidity, described later in more detail.
The study was designed according to the Strengthening
the Reporting of Observational Studies in Epidemiology
(STROBE) guidelines for observational studies.13 A pre-
defined study protocol, including methods and authorship
agreements, was distributed among the participating cen-
ters. The need for ethical approval was waived by the
institutional review board at the Academic Medical Center
in Amsterdam.
Exposures and Outcomes
The DP-CAR procedure was performed in four main
variations: (1) standard DP-CAR with resection of the
common hepatic, the left gastric, and the splenic arteries,14
(2) DP-CAR with superior mesenteric or portal vein
resection, (3) DP-CAR with hepatic artery reconstruction
(for insufficient flow), and (4) DP-CAR with left gastric
artery preservation or bypass reconstruction.12 In this
study, all variations were treated equally, but the associa-
tions between the type of DP-CAR and 90-day mortality
were assessed. The primary outcome was 90-day mortality.
The secondary outcomes were major morbidity (Clavien-
Dindo 3a–4b), resection margin status, adjuvant therapy,
and survival.
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Data Extraction and Definitions
In both the design and validation cohorts, data were
extracted without using patient identifiers. For the valida-
tion cohort, we queried all three local databases for patients
who underwent DP-CAR for all indications (premalignant
or malignant) in adult patients (C 18). We updated survival
on existing cases and added new cases until 1 June 2017.
The preoperative variables included baseline character-
istics (age, sex, BMI, Charlson comorbidity index, surgical
history), performance status (ASA classification), vascular
and/or organ involvement, and tumor etiology. Procedures
were considered multivisceral if additional organ resec-
tions besides those for pancreas, gallbladder, or spleen
were performed.
The annual DP-CAR case volume per center was based
on the average number of reported procedures between 1
January 2014 and 31 December 2016. Centers with an
annual case volume of one or more were considered high-
volume DP-CAR centers, and others were considered low-
volume DP-CAR centers. Due to the lack of variability,
annual volume could not be used as a continuous variable.
Postoperative complications were scored and classified
according to the Clavien-Dindo classification.15 Interna-
tional Study Group on Pancreatic Surgery (ISGPS)
definitions were used to classify delayed gastric emptying,
post-pancreatectomy hemorrhage, and pancreatic fistu-
las.16–18 Postoperative organ space infections were defined
according to the Center for Disease Control and Prevention
(CDC) definition.19
Centers were asked to categorize resection margins
according to the Royal College of Pathologists20 definitions
as follows: R0 (distance from margin to tumor C 1 mm),
R1 (distance from margin to tumor\ 1 mm), and R2
(macroscopically positive margin). All complications were
recorded at the index hospitalization and at subsequent
readmissions up to 90 days. Survival was based on the last
recorded moment of contact between a patient and a hos-
pital staff member.
Statistical Analysis
We used predictor estimates from an internationally
designed (n = 1661) prediction model for major morbidity
(including mortality) after distal pancreatectomy (without
arterial resection) based on age, sex, ASA, BMI, multi-
visceral resection, and open versus minimally invasive
approach (Klompmaker et al., unpublished data). We cre-
ated a risk score by rounding and multiplication of the
original model (beta) coefficients.
We tested the model with the design cohort using only
baseline (intercept) adjustment and performed validation
according to the recommendations by Moons et al.11
Validation included addition of new prediction factors
based on a univariate screen and forward stepwise selection
(P\ 0.1). Both the intercept adjustment and new predictor
coefficients were calculated using the method described by
Janssen et al.21 We determined the model’s ability to
identify high- versus low-risk patients (discrimination) by
comparing the area under the receiver operating curve
(AUC)22 in both cohorts using the DeLong test.23 We
assessed the accuracy of the risk model predictions per risk
quantile using calibration plots.24
Categorical variables are reported as counts and pro-
portions and continuous variables as means ± standard
deviations and/or as medians (interquartile ranges) based
on normality. To determine statistical significance (alpha
0.05), we used Fisher’s exact test for categorical variables
and the Mann–Whitney U test for continuous variables.
Kaplan–Meier estimation was used to assess overall sur-
vival. All confidence intervals are 95%. The data were
analyzed using STATA version 15.0 (StataCorp LP, Col-
lege Station, TX, USA).
RESULTS
The study investigated 191 patients undergoing DP-
CAR between 1 January 2000 and 31 June 2017. The
design cohort contained 71 patients, and the validation
cohort comprised 120 patients. Of these patients, 33 were
treated at JHH, 37 at UPMC, and 50 at WMUH. The
median follow-up period was 309 days for the design
cohort and 447 days for the validation cohort. Overall,
90-day mortality occurred for 18 (9.5%) of the 191
patients. These 18 patients included 11 (16%) in the design
cohort and 7 (5.8%) in the validation cohort (Fig. 1).
The recorded causes of mortality were gastric ischemia
(n = 4), post-pancreatectomy hemorrhage (n = 4), pneu-
monia (n = 3), liver ischemia (n = 2), abdominal infection
(n = 2), sepsis with multi-organ failure (n = 2), and pro-
gression of residual cancer (n = 1). The additional 90-day
major morbidity (Clavien-Dindo 3a–4b) rate was 27%,
which was comparable in the two cohorts. For 174 patients
with pancreatic ductal adenocarcinoma, the R0-resection
rate was 60% (n = 113), and the median overall survival
period was 19 months (95% CI 15–25 months). The sur-
vival rate did not differ between the patients with R0 and
R1 resections.
Baseline
The baseline characteristics are presented in Table 1.
The differences between populations based on the geo-
graphic region of origin (Europe vs WMUH vs JHH/
UPMC) are presented in Supplements 1A and 1B. At
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FIG. 1 Study flow chart of data sources and year of inclusion. Two
cases were lost to follow-up evaluation within 90 days after surgery.
E-AHPBA, European-African Hepato-Pancreato-Biliary Association;
JHH, Johns Hopkins Hospital; UPMC, University of Pittsburgh
Medical Center; WMUH, Wakayama Medical University Hospital
TABLE 1 Patient
characteristics per cohort
Baseline Design cohort Validation cohort P Value
n = 71 % n = 120 %
Female sex 34 48 53 44 0.654
Median age: years (IQR) 60 (52–67) 64 (58–71) 0.009
Mean age (years) 59 ± 10.6 63 ± 10.0
Median BMI: kg/m2 (IQR) 24.0 (24–26.3) 24.4 (21.8–27.2) 0.353
Mean BMI (kg/m2) 24.3 ± 3.6 24.7 ± 4.2
ASA \ 0.001
ASA 1 12 17 2 2
ASA 2 53 75 50 42
ASA 3 or 4 6 8 68 57
Abdominal surgery history C 1 22 31 53 44 0.061
Neoadjuvant therapy \ 0.001
None 35 49 28 23
Chemotherapy 16 23 33 28
Radiotherapy 1 1 2 2
Both or chemoradiation 19 27 57 48
Hepatic artery embolization 16 23 46 38 0.037
Left gastric artery embolization 6 8 19 16 0.185
Tumor characteristics (pathology)
Ductal adenocarcinoma 62 87 113 94 0.194
Median tumor size: mm (IQR) 40 (34–50) 33 (22–45) \ 0.001
Mean tumor size (mm) 47 ± 29 34 ± 18
AJCCa
T stage C 3 64 90 101 84 0.046
N stage[ 0 46 66 64 53 0.168
M stage[ 0 1 2 4 3 0.655
IQR, interquartile range; BMI, body mass index; ASA, American Society of Anesthesiologists; AJCC,
American Joint Committee on Cancer
aBased on the 7th AJCC criteria23
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baseline, the patients from WMUH were less often female
(Europe vs WMUH vs JHH/UPMC: 48% vs 36% vs 50%,
respectively), were older (median 60 vs 68 vs 62 years),
and had a lower BMI (mean 24 vs 22 vs 26) than the
European and JHH/UPMC-series. Patients at JHH/UPMC
were more likely to have an ASA of 3 or 4 (8% vs 19% vs
84%) and more likely to receive neoadjuvant therapy (51%
vs 52% vs 94%). Hepatic and/or gastric artery embolization
was routinely performed at WMUH (92%), and in some
cases in Europe (23%), but never at JHH/UPMC (0%). The
DP-CAR procedure was most often performed for pan-
creatic ductal adenocarcinoma at JHH/UPMC (88% vs
87% vs 97%), whereas patients in Europe had larger
tumors (median 40 vs 30 vs 34 mm). Patients in Europe
and at WMUH were more likely to have a pathologic
American Joint Committee on Cancer (AJCC) T stage 3
cancer or higher (90% vs 98% vs 74%) than patients at
JHH/UPMC.
Perioperative and Long-Term Outcomes
Outcomes are presented in Table 2. Standard DP-CAR
(i.e., without venous resection or arterial reconstruction)
was most often performed at JHH/UPMC (Europe vs
WMUH vs JHH/UPMC: 73% vs 38% vs 84%, respec-
tively), and left gastric artery-sparing DP-CAR was often
performed at WMUH (46%), but never in Europe or at
JHH/UPMC. The rate of minimally invasive surgery was
18 (26%) at JHH/UPMC and negligible in Europe and at
WMUH. The rates for multivisceral resection were com-
parable between Europe and WMUH (42% vs 42%) but
lower at JHH/UPMC (30%).
The 90-day mortality rate was the highest in Europe
(16% vs 8% vs 4%), and major morbidity was highest at
WMUH (25% vs 36% vs 21%). Gastric ischemia was
observed in similar proportions (7% vs 10% vs 11%).
Strikingly, no liver ischemia was observed at JHH/UPMC
(19% vs 56% vs 0%). The JHH/UPMC cohort had the
shortest hospital stay (17 vs 21 vs 8 days) but the highest
readmission rate (13% vs 14% vs 44%). The WMUH
cohort had the highest rate of adjuvant therapy (63% vs
80% vs 74%), but the median overall survival, including
that after non-pancreatic ductal adenocarcinoma, was
highest for the JHH/UPMC cohort (20 vs 16 vs 24 months).
90-Day Mortality Risk Score
Univariate screening based on baseline characteristics
(Supplement 2A) did not show any new predictors for
90-day mortality. Notably, preoperative embolization was
not associated with lower rates of 90-day mortality.
Screening based on perioperative factors (Supplement 2B)
showed that patients without 90-day mortality were
significantly more likely to be treated at a high-volume DP-
CAR center (70% vs 39%; P = 0.015) and to have lower
operative blood loss (median 500 vs 1050 mL; P = 0.021).
The observed 90-day mortality rate was 5.5% (95% CI
1.5–9.5%) at 5 high-volume DP-CAR centers (2 US, 1
Japanese, and 2 European centers) and 18% (95% CI
7.9–28%) at 18 low-volume DP-CAR centers (P = 0.015).
Notably, the type of DP-CAR was not associated with
90-day mortality (P = 0.458).
The original risk score performance for distal pancrea-
tectomies is presented in Supplement 3. At model
application in both DP-CAR cohorts, the discriminatory
power remained stable between the design and validation
cohorts (AUC 0.79 vs 0.74; P = 0.642; Fig. 2). After
baseline adjustment for outcome incidence, calibration was
inadequate in the validation cohort (Supplement 4A). We
improved model calibration by including low- versus high-
volume DP-CAR center as a covariate in the prediction
model (Supplement 4B), based on an odds ratio (OR) of
3.71. This translated to 6.5 points on the risk score scale
(Table 3).
Final model discrimination, after addition of the volume
covariate, remained good (AUC 0.79; 95% CI, 0.68–0.90).
A clinical risk calculator is accessible online at www.panc
reascalculator.com.
DISCUSSION
In this international study of 191 patients treated at 23
centers, DP-CAR was associated with a 90-day mortality
rate of 5.5% in 5 high-volume DP-CAR centers (C 1 DP-
CAR/year) and 18% in 18 low-volume DP-CAR centers
and an additional major morbidity rate of 27%. For 174
patients with pancreatic ductal adenocarcinoma, the R0-
resection rate was 60%, and the median overall survival
period was 19 months.
We created and validated a clinical risk score for 90-day
mortality to improve patient selection. The discriminatory
power of the risk score was similar between the design and
validation cohorts (AUC 0.79 vs 0.74; P = 0.642). Low
annual DP-CAR volume (\ 1) was the strongest predictor
(OR 3.71) of 90-day mortality. The risk score included age,
sex, BMI, ASA classification, multivisceral surgery, open
versus minimally invasive surgery, and low- versus high-
volume DP-CAR center.
In a recent systematic review of DP-CAR, the 90-day
mortality rate among 113 patients was 3.5%.2 In addition,
two single-center studies reported 90-day mortality rates of
18% and 17%, respectively.8,9 The overall 90-day mortal-
ity rate in the current international multicenter study among
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TABLE 2 Outcomes per cohort
Perioperative Design cohort Validation cohort P Value
n = 71 % n = 120 %
Treated at high-volume DP-CAR centeraa 8 11 120 100 \ 0.001
Minimally invasive approach 2 3 18 15 0.012
Median operative time: min (IQR) 343 (248–425) 350 (291–447) 0.103
Mean operative time (min) 346 ± 122 380 ± 131
Additional organs resectedb
None 41 58 78 65 0.361
Stomach 9 13 8 7 0.190
Liver 3 4 3 3 0.672
Kidney 3 4 3 3 0.672
Adrenal gland 17 24 31 26 0.864
DP-CAR type \ 0.001
Standard DP-CAR 52 73 79 66
SMV/portal vein resectionc 10 14 14 12
Hepatic artery reconstruction 9 13 5 4
Left gastric artery preservation/reconstruction 0 – 23 19
Median EBL: mL (IQR) 560 (350–1450) 560 (300–1100) 0.374
Mean EBL (mL) 1015 ± 1145 996 ± 1502
Blood transfusion for bleeding (\ 72 h) 22 33 17 14 0.005
Residual status overall 0.206
R0 ([ 1-mm margin) 38 55 75 63
R1 (\ 1-mm margin) 29 42 38 32
R2 (macroscopically positive) 2 3 1 1
90-Day outcomes
Mortality 11 16 7 6 0.077
Clavien-Dindo 3a–4b complication 18 25 33 28 0.866
Post-pancreatectomy hemorrhaged 6 8 9 8 0.787
Liver ischemia/infarction 12 19 28 23 0.575
Gastric ischemia 5 7 13 11 0.452
Abdominal cavity infection 4 6 23 19 0.016
Pancreatic fistula grade B/Cd 15 21 27 23 0.858
Delayed gastric emptying grade B/Cd 11 15 12 10 0.495
Reoperation 10 14 6 5 0.018
Median hospital stay: days (IQR) 17 (11–26) 11 (7–21) 0.005
Mean hospital stay (days) 20 ± 14 18 ± 21
Unplanned readmission 9 13 38 32 0.005
Long-term outcomes
Adjuvant treatment 0.261
None 23 32 26 22
Chemotherapy 41 58 72 60
Radiotherapy 2 3 3 3
Both or chemoradiation 2 3 10 8
Unknown 3 4 10 8
Median follow-up: days (IQR) 309 (128–617) 447 (207–939) 0.019
Median overall survival: months (95% CI) 20 (10–36) 21 (16–26)
IQR, interquartile range; SMV, superior mesenteric vein; EBL, estimated blood loss; AJCC, American Joint Committee on Cancer; ASA, American Society of
Anesthesiologists; CI, confidence interval
aMean volume of 1 per year between 1 January 2014 and 31 December 2016
bOther than celiac axis, gallbladder, pancreas, or spleen
cExcluding side bite
dInternational Study Group on Pancreatic Surgery (ISGPS) definition16–18
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191 patients was 9.5%. Therefore, it seems likely that
publication bias affected prior estimates of the 90-day
mortality rate in the systematic review.
On the other hand, our study confirmed previous find-
ings on the volume-outcome relationship in pancreas
surgery. For example, a nationwide registry study25 found a
significantly increased risk of 90-day mortality after pan-
creatoduodenectomy (OR 2.59; 95% CI 1.32–5.09) in the
lowest- versus the highest-volume centers (cutoff, 40
pancreatoduodenectomies per year). Similar volume-out-
come associations for 90-day mortality have been found by
others.22,26
We noted a few interesting variations in clinical strate-
gies between the three very-high-volume centers in the
validation cohort. First, prolonged neoadjuvant treatment is
routinely applied (FOLFIRINOX or nab-paclitaxel plus
gemcitabine, up to 8 cycles) at JHH and UPMC to assess
both tumor biology (aggressiveness) and patient fitness.
Second, although some multivisceral resections were nec-
essary during the operation, preoperatively apparent tumor
involvement of additional organs is an absolute con-
traindication for surgery at all three centers. Third, all three
centers recognize the need to preserve as much organ
perfusion as possible. At WMUH, this is addressed by
routine performance of preoperative left gastric and hepatic
artery embolization or by preservation or reconstruction of
the left gastric artery (middle colic artery bypass). At JHH
and UPMC, surgeons refrain from resecting the superior
mesenteric artery and perform only partial portal vein
resection (side-bites/wedge resection) when involvement is
detected intraoperatively. This could explain the low liver
ischemia rates and superior survival at UPMC/JHH.
Unfortunately, the subgroups in this study remained too
small to study the effect of these strategies on 90-day
mortality.
In addition to the clinical strategies described earlier,
outcomes such as 90-day mortality after DP-CAR may be
improved by using the proposed clinical risk score.
Avoiding DP-CAR for high-risk patients would be an
obvious step to lowering mortality. Given the limited sur-
vival benefit after resection of pancreatic ductal
adenocarcinoma, a mortality risk exceeding 10–20% would
not seem justified. Alternatively, the clinical risk score
should be used for baseline risk adjustment in future
studies comparing specific techniques or center
performance.
Despite these practical applications, continuous model
reevaluation is important to maintain accuracy. For
example, further centralization of pancreatic surgery may
shift the definition of ‘‘high-volume’’. Notably, the high-
volume centers in this study all performed more than 90
(median 175; interquartile range [IQR], 105–293) pancre-
atic resections per year.
This study had some limitations. First, despite the large
cohorts, it lacked sufficient power to detect less obvious
predictors of 90-day mortality. As a result, we may have
missed predictors in our clinical risk score. Second, to
increase power, all DP-CAR variations were grouped
together, whereas outcomes in fact may differ. Future
studies should aim to study the differences in long-term
outcomes between DP-CAR variations. Third, surgeon and
center experience are perhaps the most important deter-
minant of a successful outcome after surgery. Although this
is partly reflected in the risk score, surgeons should always
consider their individual training and experience. Fourth,
we used annual case volume as a surrogate marker for the
experience of the surgical team. We acknowledge that this
may not capture the full complexity of factors that con-
tribute to improved outcomes at these centers. Moreover,
referral patterns may shift and/or external expertise may be
acquired. Therefore, the high-volume threshold presented
in this study should be used only as a starting point for
further discussion on centralization. Fifth, median overall
survival times should be interpreted with caution because
the median follow-up time was 385 days in both cohorts
combined. Sixth, there was a considerable time differential
(4–7 years) between the design and validation cohorts,
which may have introduced a time-dependent bias.
Although this may be the case for the effect of chemo-/
radiotherapy regimens on survival, we previously ruled out
any differences over time for morbidity and mortality
outcomes in the European population.7 Finally, although
arguably part of the most important outcomes in oncologic
surgery, quality-of-life measures were not available for this
retrospective study.
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FIG. 2 Discrimination curves for 90-day mortality prediction.
Receiver operator curves (ROC) for the 90-day mortality prediction
model. The area under the curve (AUC) was 0.79 (95% confidence
interval [CI], 0.65–0.93) in the design cohort (n = 71) and 0.74 (95%
CI, 0.56–0.92) in the validation cohort (n = 120). The difference is
not significant (P = 0.642)
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This study has some important practical implications
and offers important starting points for further study. First,
although the consensus that rare and high-risk procedures
such as DP-CAR should be limited to very-high-volume
centers is well established, optimal volume thresholds for
this procedure have not been determined to date. Even a
selective approach (e.g., favorable patient risk factors) to
DP-CAR should be avoided at low-volume centers because
this would decrease the annual DP-CAR volume even
further.
Second, important practice variations between high-
volume DP-CAR centers, such as the application of pre-
operative embolization or chemoradiotherapy, were noted.
Although these variations did not modify the effect of
volume on 90-day mortality in this study, they may indeed
have an impact on long-term outcomes such as survival.
These effects are likely to be more evident in a broader
study setting such as in the Arterial Study Network.27
Third, the actual impact of improved patient selection on
outcomes after DP-CAR needs further study.
In conclusion, this study presents the largest interna-
tional series on DP-CAR to date and includes a validated
clinical risk score for 90-day mortality. The main finding is
that annual DP-CAR case volume is the most important
predictor for 90-day mortality. Future studies should aim at
(prospectively) validating the clinical risk score, which was
made available online at www.pancreascalculator.com.
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TABLE 3 Risk score adjustmenta
Risk factor Original b coefficient Original score Adjusted b coefficient Adjusted score
Age per 10 years (40–90) 0.11 0.5 – 0.5
Female with ASA 1–2 0 0 – 0
Female with ASA 3–4 0.52 2.5 – 2.5
Male (any ASA) 0.88 4.5 – 4.5
BMI per 10 points (20–50) 0.39 2 – 2
Multivisceral resectiona 0.42 2 – 2
Open surgery 0.49 2.5 – 2.5
High-volume DP-CAR centerb – – - 1.31 - 6.5
Intercept - 2.82 – - 3.96 –
Total 6–23.5 0–23.5
Model coefficients were obtained from the original design dataset7 to determine the risk score by rounding and multiplication. The intercept was
adjusted for the risk of 90-day mortality in the design cohort (n = 71); a coefficient for high-volume center was added
ASA, American Society of Anesthesiologists; BMI, body mass index; DP-CAR, distal pancreatectomy with celiac axis resection
aDefinition: other than celiac axis, gallbladder, pancreas, or spleen
bAnnual volume C 1 DP-CAR
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